Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia | Zendy

Ali Osman Saatçi | Zendy; Zi̇ya Ayhan | Zendy; Şefik Can İpek | Zendy; Meltem Söylev Bajin | Zendy

Open Access

Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia

Author(s) -

Ali Osman Saatçi,

Zi̇ya Ayhan,

Şefik Can İpek,

Meltem Söylev Bajin

Publication year - 2018

Publication title -

turkish journal of ophthalmology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.654

H-Index - 10

eISSN - 2147-2661

pISSN - 1300-0659

DOI - 10.4274/tjo.09076

Subject(s) - sympathetic ophthalmia , medicine , aflibercept , ophthalmology , choroidal neovascularization , complication , ranibizumab , surgery , visual acuity , chemotherapy , bevacizumab , uveitis

Choroidal neovascular membrane (CNV) is a very rare complication in patients with sympathetic ophthalmia. We hereby report a 38-year-old man who developed a type 2 CNV in his only seeing (left) eye while under systemic steroid treatment. Systemic therapy was revised and a total of 5 intravitreal aflibercept injections (2 mg each) were administered over a period of 8 months. Good anatomic and functional outcome was noted at the last visit. Anti-vascular endothelial growth factor injection may be an important adjunct to systemic therapy in eyes with with sympathetic ophthalmia-associated CNV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research